Biological Therapeutic Products

Conferences & Courses
ImVacS: The Immunotherapies and Vaccines Summit ImVacS: The Immunotherapies and Vaccines Summit
August 11-14, 2014 | Boston, MA
The Clinical Genome Conference, June 10-12, 2014 The unstoppable march of genomics into clinical practice continues.

Novel Vaccines-One: Adjuvants, TLRs & DNA Vaccines Novel Vaccines-One: Adjuvants, TLRs & DNA Vaccines
August 11-12, 2014 | Boston, MA
The Clinical Genome Conference, June 10-12, 2014 The unstoppable march of genomics into clinical practice continues.

Immunomodulatory Therapeutic Antibodies for Cancer Immunomodulatory Therapeutic Antibodies for Cancer
August 11-12, 2014 | Boston, MA
The Clinical Genome Conference, June 10-12, 2014 The unstoppable march of genomics into clinical practice continues.




Life Science Media Library
Phage & Yeast Display Libraries Phage & Yeast Display Libraries
May 4, 2014 |
This workshop is meant to bring the scientist up to speed on the display technologies covered by the main conference and is tailored for both the novice and those with experience in display technologies. The workshop will provide an overview of: Phage display and construction of phage-displayed scFv and Fab libraries Yeast display and construction of yeast-displayed scFv and Fab libraries Selection and screening technologies that are compatible with phage and yeast-display libraries Combining phage and yeast display for antibody selection and epitope identification Integrating deep sequencing into the antibody selection pipeline
Accelerated Stability Testing of Biologics Accelerated Stability Testing of Biologics
August 20, 2013 |
This digital course will aim to guide the researcher in designing studies for accelerated stability testing of biologics. The course will begin with basic underlying concepts governing protein drug product stability, and focus on design principles for meaning stress and accelerated stability testing of not only the protein of interest but also of excipients and primary packaging components. Strategies to handle complexities arising from their interactions will also be discussed.
Antibody-Drug Conjugates-Engineering for Success Antibody-Drug Conjugates-Engineering for Success
January 22, 2013 |
This course provides a detailed look into the discovery, characterization, and manufacturing of Antibody-Drug Conjugates, with a particular focus on safety issues. Featured is an in-depth and extensive case study from Genentech about their use of antibody-drug conjugates in a robust bio-oncology program, including a focus on risk mitigation and risk minimization strategies. This talk is followed by a presentation about Sutro Biopharma’s Open Cell Free Synthesis (OCFS) technology for screening, selecting and formulating ADCs. Finally, an excellent overview of the infrastructure required to produce these molecules is presented by Lonza. All three presentations are filled with first-hand insights and practical approaches to successfully developing these potent biologics.




Publications, Reports, & Whitepapers
Vaccines: The End of Illness
This report analyzes recent trends in medicinal chemistry and evaluates their significance for advancing R&D productivity. We consider technological modalities and market dynamics, with an emphasis on outsourcing and user views on the implications of current practices.
MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics
This report analyzes recent trends in medicinal chemistry and evaluates their significance for advancing R&D productivity. We consider technological modalities and market dynamics, with an emphasis on outsourcing and user views on the implications of current practices.
Ocular Disorders: Rising Therapeutics, Technologies, and Devices
New to Insight Pharma Reports is: Ocular Disorders: Rising Therapeutics, Technologies, and Devices. This report covers several companies and their approach to targeting ocular diseases including wet and dry age-related macular degeneration (AMD) while also providing alternative therapeutic options for various ocular complications.